Humana (NYSE:HUM) 2026 Conference Summary Company Overview - **Company**: Humana Inc. - **Industry**: Healthcare and Medicare Advantage Key Themes and Commitments - Humana reaffirmed its commitment to achieving a stable Medicare Advantage (MA) margin of at least 3% and restoring earnings power by 2028, as stated during the Investor Day in June 2025 [2][3] - Adjustments to benefits will be necessary to accommodate the current medical cost trends and funding environment [3][12] Lifetime Value of Members - The concept of lifetime value is emphasized, indicating that the economic value of a member increases significantly from year one to year two, primarily due to lower retention costs and better member management [3][4] - A stable MA margin is essential for maximizing member retention and minimizing attrition [4][5] Membership Metrics - During the Annual Enrollment Period (AEP), over 1 million new members were added, with approximately 70% being switchers from other plans, which are generally more economically favorable in the first year [17][18] - Humana absorbed about 12% of plan exits, indicating a positive mix of new members coming from other plans rather than exits [18][19] - 70% of new members are enrolled in four-star or better contracts, and 75% are acquired through higher-quality sales channels [18][19] Sales Channel Strategy - Humana has focused on improving the quality of its sales channels by trimming lower-performing call centers and broker partners, which has led to a better membership mix [22] Margin Profiles and Member Engagement - The company expects to double margins despite headwinds from Star ratings, with a consistent mix of HMO and PPO plans compared to previous years [23][26] - Engagement initiatives have been enhanced, with proactive outreach to new members to improve their onboarding experience and overall satisfaction [54][56] Star Ratings and Operational Performance - Humana is optimistic about its Star Ratings performance, having made significant strides in operational metrics and member engagement [63][64] - Recent changes proposed by CMS to focus more on health outcomes rather than administrative metrics are supported by Humana, as they align with the company's ongoing efforts to improve quality [70][71] Part D and PDP Margins - Humana is guiding towards break-even margins for its Part D business, with expectations for more consistent profitability as the program stabilizes [72][74] - The company views its PDP as a strategic starter product that can lead to further engagement in MAPD plans [75] Regulatory Environment and Rate Notice - The company expressed concerns about the implications of the preliminary rate notice from CMS, emphasizing the need for adjustments to maintain benefits amidst rising costs [80][81] - Humana is actively engaging with policymakers to advocate for necessary changes that would benefit members [81] CenterWell and Acquisitions - Recent acquisitions in Florida are aimed at filling geographic gaps in Humana's CenterWell portfolio, enhancing operational fit and expanding the primary care footprint [102][103] - The company emphasizes that both the Medicare Advantage and CenterWell businesses must stand alone financially [106] Conclusion - Humana is strategically positioned to navigate the current healthcare landscape, focusing on member retention, quality improvement, and operational efficiency while adapting to regulatory changes and market dynamics. The company remains committed to its long-term financial goals and enhancing member value through targeted initiatives.

Group 1 - Bretton Fund returned 1.44% in Q4 2025, underperforming the S&P 500 Index which returned 2.66% during the same period [1] - For the full year 2025, the Fund achieved a return of 11.58%, compared to 17.88% for the S&P 500 Index [1] - The firm does not view the overall market as being in bubble territory but acknowledges it is modestly elevated, particularly concerning the artificial intelligence sector [1] Group 2 - UnitedHealth Group Incorporated (NYSE:UNH) is highlighted as a significant stock in the Bretton Fund's portfolio, with a market capitalization of $261.978 billion [2] - The stock closed at $289.21 per share on March 03, 2026, with a one-month return of 4.82%, but it has lost 39.24% over the past 52 weeks [2] - UnitedHealth's performance negatively impacted the Fund by -1.1% due to unexpected surges in health costs for its enrollees [3] Group 3 - UnitedHealth faced challenges in 2025, including a Department of Justice investigation into its Medicare Advantage coding practices [3] - Although UnitedHealth won a coding case from the Obama Administration, the situation highlighted the difficulties of navigating regulatory investigations [3]

Core Viewpoint - Alignment Healthcare, Inc. has announced a public offering of 13,167,733 shares of its common stock by an affiliate of General Atlantic, L.P., with the company not receiving any proceeds from this sale [1] Group 1: Offering Details - The offering is underwritten by J.P. Morgan [2] - It is made pursuant to a shelf registration statement on Form S-3, effective as of March 2, 2026 [3] - The offering will be conducted via a prospectus supplement and an accompanying prospectus, available for free on the SEC website [3] Group 2: Company Overview - Alignment Healthcare is focused on providing high-quality, low-cost care for Medicare Advantage members, emphasizing a mission-driven approach [5] - The company utilizes a customized care model, a 24/7 concierge care team, and proprietary technology, AVA®, to enhance member care [5] - Alignment Healthcare aims to expand its offerings and national presence while prioritizing senior care [5]

Core Insights - UnitedHealth Group Incorporated (UNH) has launched the Rural Payment Acceleration Pilot, aimed at alleviating cash-flow pressures for independent rural hospitals by reducing Medicare Advantage reimbursement timelines by approximately 50% [1][8] Group 1: Initiative Overview - The six-month pilot program will decrease average payment cycles from less than 30 days to under 15 days in selected markets including Oklahoma, Idaho, Minnesota, and Missouri [1][8] - This initiative addresses the critical issue of cash flow for rural hospitals, where timely payments are essential for managing operating expenses such as staffing and medical supplies [2][3] Group 2: Strategic Implications - By expediting payments, UNH aims to stabilize cash flow, reduce reliance on short-term borrowing, and mitigate the risk of service disruptions in rural communities [3][4] - If successful, the program could serve as a scalable model for enhancing the financial stability of rural health systems, indicating a potential shift towards a more sustainable, payer-led approach [4] Group 3: Competitive Landscape - Competitors such as Elevance Health, Inc. (ELV) and Humana Inc. (HUM) are also focusing on expanding their Medicare Advantage presence and improving operational efficiencies [5][6] - Elevance Health emphasizes value-based care and localized networks, while Humana prioritizes internal efficiency initiatives to support growth in its Medicare Advantage business [5][6] Group 4: Financial Performance - UnitedHealth's shares have increased by 14.5% over the past six months, outperforming the industry average rise of 10.1% [7] - The company trades at a forward price-to-earnings ratio of 18.90, which is above the industry average of 15.74, and holds a Value Score of A [9] - The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is projected at $16.30 per share, reflecting a 41.1% decline from the previous year [10]

Core Insights - Ariel Global Fund's third-quarter 2025 performance was influenced by global equity rallies, AI enthusiasm, resilient corporate earnings, and the first U.S. rate cut of the year, with the fund returning +4.99% compared to +7.62% for the MSCI ACWI Index [1] Group 1: Fund Performance - The Ariel Global Fund traded +4.99% higher in Q3 2025, underperforming the MSCI ACWI Index which returned +7.62% and the MSCI ACWI Value Index which returned +6.13% [1] - The fund's performance was driven by factors such as AI enthusiasm and targeted policy easing across key regions [1] Group 2: Humana Inc. (NYSE:HUM) Overview - Humana Inc. offers medical and specialty insurance products, with a one-month return of -18.64% and a 52-week loss of 20.37%, closing at $234.10 per share with a market capitalization of $28.156 billion on November 18, 2025 [2] - The fund initiated a position in Humana, focusing on its Medicare Advantage, Medicaid, and specialty healthcare services [3] Group 3: Humana Inc. Performance and Outlook - Humana's largest Medicare Advantage plan, H5216, was downgraded from 4.5 to 3.5 Stars in 2025, affecting eligibility for federal bonus payments in 2026 [3] - There is optimism regarding Humana's potential to regain a higher Star rating in 2027, which could restore access to quality-based federal bonuses [3] Group 4: Hedge Fund Interest - Humana Inc. was held by 69 hedge fund portfolios at the end of Q2 2025, a decrease from 73 in the previous quarter [4] - While Humana is recognized for its investment potential, certain AI stocks are viewed as having greater upside potential and less downside risk [4]

Core Viewpoint - CVS Health has experienced a significant stock increase of 76% since January, despite market volatility and economic challenges, suggesting it may still be reasonably valued based on its forward earnings multiple of 10.7 compared to the healthcare industry's average of 17.3 [1] Financial Performance - CVS Health's revenue for the second quarter rose by 8.4% year over year to $98.9 billion, with adjusted earnings per share at $1.81, slightly down from $1.83 in the previous year, indicating a better-than-expected performance that exceeded Wall Street's forecasts [5] - The Medicare Advantage (MA) unit has faced challenges with operating margins previously reported between negative 4.5% to negative 5%, but recent results have shown improvement [3][5] Future Outlook - CVS is implementing a strategy to address its MA-related issues by scaling back operations and focusing on improving margins rather than volume, which positions the company favorably for long-term growth [8] - The company's extensive presence in the U.S. healthcare market and established relationships with key industry players contribute to its attractive prospects [8]

Core Viewpoint - UnitedHealth Group Incorporated (NYSE: UNH) has experienced a significant underperformance, with a -21% drop in stock price compared to a 5% gain in the S&P 500, primarily due to structural weaknesses in its Medicare Advantage pricing and utilization [1] Financial Performance - The stock has underperformed the market, indicating potential issues in financial health and market positioning [1] Market Positioning - The company faces challenges in its Medicare Advantage segment, which may impact its competitive positioning and growth prospects [1] Investment Considerations - The analysis suggests a need for careful evaluation of UnitedHealth's pricing strategies and utilization metrics in the Medicare Advantage space to identify potential recovery or further risks [1]